Marta Kulis

Marta Kulis

Auto-generated profile, based on publicly available information

Marta Kulis

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2024 in Blood
Verified
Journal Article
Open access
DDDaphné Dupéré-Richer
Daphné Dupéré-Richer
ARAlberto Riva
Alberto Riva
BBBenjamin G. Barwick
Benjamin G. Barwick
SMSayantan Maji
Sayantan Maji
HRHeidi Casellas Román
Heidi Casellas Román
JLJonathan D. D Licht
Jonathan D. D Licht
The histone H3 at lysine 27 (H3K27) demethylase lysine demethylase 6A (KDM6A) is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome-wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA, which encode regulators of major histocompatibility complex genes. Patient data indicate that NLRC5 and CIITA are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A, and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of major histocompatibility complex expression, offering a strategy to restore immunogenicity of KDM6A-deficient tumors. Loss of Kdm6a in Kirsten rat sarcoma virus (K-RAS)-transformed murine fibroblasts led to increased growth in vivo associated with decreased T-cell infiltration.

12 December 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
MSMarta Sureda-Gómez
Marta Sureda-Gómez
PBPatricia Balsas
Patricia Balsas
MRMarta-Leonor Rodríguez
Marta-Leonor Rodríguez
FNFerran Nadeu
Ferran Nadeu
ABAnna De Bolòs
Anna De Bolòs
VAVirginia Amador
Virginia Amador
SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem cells (CSC) of some tumors. Although CSC have been isolated from primary MCL, their relationship to SOX11 expression and contribution to MCL pathogenesis and clinical evolution remain unknown. Here, we observed enrichment in leukemic and hematopoietic stem cells gene signatures in SOX11+ compared to SOX11– MCL primary cases. Musashi-2 (MSI2) emerged as one of the most significant upregulated stem cell-related genes in SOX11+ MCLs. SOX11 is directly bound to the MSI2 promoter upregulating its expression in vitro. MSI2 intronic enhancers were strongly activated in SOX11+ MCL cell lines and primary cases. MSI2 upregulation was significantly associated with poor overall survival independently of other high-risk features of MCL. MSI2 knockdown decreased the expression of genes related to apoptosis and stem cell features and significantly reduced clonogenic growth, tumor cell survival and chemoresistance in MCL cells. MSI2-knockdown cells had reduced tumorigenic engraftment into mice bone marrow and spleen compared to control cells in xenotransplanted mouse models. Our results suggest that MSI2 might play a key role in sustaining stemness and tumor cell survival, representing a possible novel target for therapeutic interventions in MCL.

19 September 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
MKMarta Kulis
Marta Kulis
JMJose Ignacio Martin‐Subero
Jose Ignacio Martin‐Subero

12 December 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CSCharlotte Syrykh
Charlotte Syrykh
BPBerta Pons-Brun
Berta Pons-Brun
NRNúria Russiñol
Núria Russiñol
HPHeribert Playa-Albinyana
Heribert Playa-Albinyana
TBTycho Baumann
Tycho Baumann
FNFerran Nadeu
Ferran Nadeu


15 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRamon Massoni-Badosa
Ramon Massoni-Badosa
GIGiovanni Iacono
Giovanni Iacono
CMCatia Moutinho
Catia Moutinho
MKMarta Kulis
Marta Kulis
NPNúria Palau
Núria Palau
HHHolger Heyn
Holger Heyn
Robust protocols and automation now enable large-scale single-cell RNA and ATAC sequencing experiments and their application on biobank and clinical cohorts. However, technical biases introduced during sample acquisition can hinder solid, reproducible results and a systematic benchmarking is required before entering large-scale data production. Here, we report the existence and extent of gene expression and chromatin accessibility artifacts introduced during sampling and identify experimental and computational solutions for their prevention.